JP4058114B2 - クラリスロマイシンの結晶形態０ - Google Patents

クラリスロマイシンの結晶形態０ Download PDF

Info

Publication number
JP4058114B2
JP4058114B2 JP53437298A JP53437298A JP4058114B2 JP 4058114 B2 JP4058114 B2 JP 4058114B2 JP 53437298 A JP53437298 A JP 53437298A JP 53437298 A JP53437298 A JP 53437298A JP 4058114 B2 JP4058114 B2 JP 4058114B2
Authority
JP
Japan
Prior art keywords
methylerythromycin
solvate
powder
ray diffraction
peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP53437298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000509725A (ja
Inventor
スパントン，ステイーブン・ジイ
ヘンリー，ロジヤー・エフ
リリー，デイビツド・エイ
リウ，チー−ホウア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25136084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4058114(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2000509725A publication Critical patent/JP2000509725A/ja
Application granted granted Critical
Publication of JP4058114B2 publication Critical patent/JP4058114B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP53437298A 1997-01-17 1997-12-19 クラリスロマイシンの結晶形態０ Expired - Lifetime JP4058114B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/785,623 1997-01-17
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin
PCT/US1997/023607 WO1998031699A1 (en) 1997-01-17 1997-12-19 Crystal form 0 of clarithromycin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003311358A Division JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態０

Publications (2)

Publication Number Publication Date
JP2000509725A JP2000509725A (ja) 2000-08-02
JP4058114B2 true JP4058114B2 (ja) 2008-03-05

Family

ID=25136084

Family Applications (3)

Application Number Title Priority Date Filing Date
JP53437298A Expired - Lifetime JP4058114B2 (ja) 1997-01-17 1997-12-19 クラリスロマイシンの結晶形態０
JP2003311358A Withdrawn JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態０
JP2008327022A Expired - Lifetime JP5190350B2 (ja) 1997-01-17 2008-12-24 クラリスロマイシンの結晶形態０

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2003311358A Withdrawn JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態０
JP2008327022A Expired - Lifetime JP5190350B2 (ja) 1997-01-17 2008-12-24 クラリスロマイシンの結晶形態０

Country Status (18)

Country Link
US (1) US5945405A (OSRAM)
EP (1) EP1077988A1 (OSRAM)
JP (3) JP4058114B2 (OSRAM)
KR (1) KR100567149B1 (OSRAM)
CN (1) CN1174991C (OSRAM)
AR (3) AR011077A1 (OSRAM)
AU (1) AU735598B2 (OSRAM)
BR (1) BR9714287A (OSRAM)
CA (4) CA2387356C (OSRAM)
CZ (1) CZ297433B6 (OSRAM)
DE (1) DE97951771T1 (OSRAM)
ES (1) ES2173058T1 (OSRAM)
IL (1) IL130255A0 (OSRAM)
NZ (1) NZ336073A (OSRAM)
TR (1) TR199901578T2 (OSRAM)
TW (1) TW574224B (OSRAM)
WO (1) WO1998031699A1 (OSRAM)
ZA (1) ZA98116B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009137975A (ja) * 1997-01-17 2009-06-25 Abbott Lab クラリスロマイシンの結晶形態０

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) * 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
PT1254146E (pt) * 1999-12-16 2005-10-31 Teva Pharma Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU2578701A (en) 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
CN1193036C (zh) * 2000-03-15 2005-03-16 韩美药品工业株式会社 制备甲红霉素－克拉霉素ⅱ型晶体的方法
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
EP1411899B1 (en) * 2001-08-01 2009-03-11 Novartis AG Taste masking composition
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
PT915899E (pt) * 1996-07-29 2004-11-30 Abbott Lab Preparacao da forma cristalina ii da eritromicina
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009137975A (ja) * 1997-01-17 2009-06-25 Abbott Lab クラリスロマイシンの結晶形態０

Also Published As

Publication number Publication date
CZ242699A3 (cs) 1999-11-17
JP5190350B2 (ja) 2013-04-24
AR039667A2 (es) 2005-03-02
US5945405A (en) 1999-08-31
ZA98116B (en) 1998-07-08
CA2419499A1 (en) 1998-07-23
AR039666A2 (es) 2005-03-02
JP2000509725A (ja) 2000-08-02
AU5532698A (en) 1998-08-07
JP2004075689A (ja) 2004-03-11
CN1244869A (zh) 2000-02-16
IL130255A0 (en) 2000-06-01
KR20000070220A (ko) 2000-11-25
EP1077988A1 (en) 2001-02-28
WO1998031699A1 (en) 1998-07-23
BR9714287A (pt) 2000-04-18
CA2277274C (en) 2003-05-27
KR100567149B1 (ko) 2006-04-04
CA2277274A1 (en) 1998-07-23
CZ297433B6 (cs) 2006-12-13
CA2387361C (en) 2003-05-27
NZ336073A (en) 2001-01-26
DE97951771T1 (de) 2004-07-08
CA2387361A1 (en) 1998-07-23
CA2387356A1 (en) 1998-07-23
JP2009137975A (ja) 2009-06-25
TW574224B (en) 2004-02-01
CN1174991C (zh) 2004-11-10
ES2173058T1 (es) 2002-10-16
AU735598B2 (en) 2001-07-12
TR199901578T2 (xx) 1999-09-21
AR011077A1 (es) 2000-08-02
CA2387356C (en) 2003-05-27

Similar Documents

Publication Publication Date Title
JP5190350B2 (ja) クラリスロマイシンの結晶形態０
CN1216892C (zh) 甲红霉素的晶形i
US6987175B2 (en) Processes for preparing clarithromycin polymorphs
AU752877B2 (en) Novel crystalline forms of an antiviral benzimidazole compound
HUP0204091A2 (hu) Eljárások a clarithromycin polimorf módosulatainak előállítására és az új polimorf IV módosulat, és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JP2004075689A5 (OSRAM)
TWI530501B (zh) 純化十字孢靈素之方法
KR100888519B1 (ko) 가티플록사신의 소아 제제
CN101812102B (zh) 6-o-甲基红霉素a晶型v
WO2014023027A1 (zh) 盐酸埃罗替尼多晶型物及其制备方法
AU2005203314A1 (en) Processes for preparing clarithromycin polymorphs
CZ20003709A3 (cs) Nové krystalické formy protivirivé benzimidazolové sloučeniny

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20050224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20051102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20051108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060209

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20060518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071217

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101221

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111221

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121221

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121221

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131221

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term